RT Journal Article
SR Electronic
T1 North West London Covid-19 Vaccination Programme: Real-world evidence for Vaccine uptake and effectiveness
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.08.21254580
DO 10.1101/2021.04.08.21254580
A1 B Glampson
A1 J Brittain
A1 Amit Kaura
A1 A Mulla
A1 L Mercuri
A1 S Brett
A1 P Aylin
A1 T Sandall
A1 I Goodman
A1 J Redhead
A1 K Saravanakumar
A1 E K Mayer
YR 2021
UL http://medrxiv.org/content/early/2021/04/10/2021.04.08.21254580.abstract
AB Objective To assess the early vaccine administration coverage and vaccine effectiveness and outcome data across an integrated care system of eight CCGs leveraging a unique population-level care datasetDesign Retrospective cohort study.Setting Individuals eligible for COVID 19 vaccination in North West London based on linked primary and secondary care data.Participants 2,183,939 individuals eligible for COVID 19 vaccinationResults During the NWL vaccine programme study time period 5.88% of individuals declined and did not receive a vaccination. Black or black British individuals had the highest rate of declining a vaccine at 16.14% (4,337). There was a strong negative association between deprivation and rate of declining vaccination (r=-0.94, p<0.01) with 13.5% of individuals declining vaccination in the most deprived postcodes compared to 0.98% in the least deprived postcodes.In the first six days after vaccination 344 of 389587 individuals tested positive for COVID-19 (0.09%). The rate increased to 0.13% (525/389,243) between days 7 and 13, before then gradually falling week on week.At 28 days post vaccination there was a 74% (HR 0.26 (0.19-0.35)) and 78% (HR 0.22 (0.18-0.27)) reduction in risk of testing positive for COVID-19 for individuals that received the Oxford/Astrazeneca and Pfizer/BioNTech vaccines respectively, when compared with unvaccinated individuals.After vaccination very low rates of hospital admission were seen in individuals testing positive for COVID-19 (0.01% of all patients vaccinated).Conclusions This study provides further evidence that a single dose of either the Pfizer/BioNTech vaccine or the Oxford/Astrazeneca vaccine is effective at reducing the risk of testing positive for COVID-19 up to 60 days across all adult age groups, ethnic groups, and risk categories in an urban UK population. There was no difference in effectiveness up to 28 days between the Oxford/Astrazeneca and Pfizer/BioNtech vaccines.In those declining vaccination higher rates were seen in those living in the most deprived areas and in Black and Black British groups.There was no definitive evidence to suggest COVID-19 was transmitted as a result of vaccination hubs during vaccine the administration roll-out in NWL, and the risk of contracting COVID-19 and/or becoming hospitalised after vaccination has been demonstrated to be very low in the vaccinated population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was enabled by the Imperial Clinical Analytics Research and Evaluation (iCARE) environment and Whole Systems Integrated Care and used the iCARE & WSIC team and data resources (https://imperialbrc.nihr.ac.uk/facilities/icare/). The research was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC), the National Institute of Health Research (NIHR) Imperial Patient Safety Translational Research Centre and the NW London NIHR Applied Research Collaboration. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was undertaken within a Research Database that was given favourable Ethics approval by the West Midlands - Solihull Research Ethics Committee. REC reference: 18/WM/0323. IRAS project ID: 252449.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharingWe are unable to extract or publish patient level data from iCARE and Whole systems integrated care due to data protection restrictions. Any request to access data can be made to Nwlccgs.covid19IG{at}nhs.net referring to the title of this paper.